AtriCure (NASDAQ: ATRC) insider transactions
In the twelve months to 10 November 2026, executives and directors of AtriCure reported 19 open-market sales of 116,890 shares ($5.1m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Johnson B Kristine | Director | Open-market sale | −2,452 | $58.48 | 53,502 | Form 4 |
| 4 November 2026 | Privitera Salvatore | Chief Technical Officer | Open-market sale, 10b5-1 plan | −8,404 | $65.00 | 134,341 | Form 4 |
| 23 September 2026 | Privitera Salvatore | Chief Technical Officer | Open-market sale, 10b5-1 plan | −4,519 | $60.00 | 142,745 | Form 4 |
| 11 September 2026 | Groves Regina E | Director | Open-market sale | −5,313 | $54.22 | 34,546 | Form 4 |
| 8 September 2026 | Privitera Salvatore | Chief Technical Officer | Open-market sale, 10b5-1 plan | −3,657 | $55.00 | 147,264 | Form 4 |
| 2 September 2026 | Privitera Salvatore | Chief Technical Officer | Open-market sale, 10b5-1 plan | −7,763 | $52.50 | 150,921 | Form 4 |
| 24 August 2026 | Dahlquist Karl S. | Chief Legal Officer | Open-market sale | −9,370 | $48.89 | 87,319 | Form 4 |
| 5 August 2026 | Prange Karen | Director | Open-market sale | −3,564 | $38.80 | 22,809 | Form 4 |
| 5 August 2026 | Yuen Maggie | Director | Open-market sale | −3,500 | $38.42 | 14,015 | Form 4 |
| 30 July 2026 | Carrel Michael H | President, CEO, & Director | Gift | −700 | — | 778,434 | Form 4 |
| 30 July 2026 | Carrel Michael H | President, CEO, & Director | Gift | −4,000 | — | 774,434 | Form 4 |
| 29 July 2026 | Noznesky Justin J | Chief Mktg & Strategy Officer | Open-market sale | −6,182 | $38.80 | 100,219 | Form 4 |
| 28 July 2026 | Wehrwein Sven | Director | Option exercise | +25,000 | $19.95 | 65,518 | Form 4 |
| 28 July 2026 | Wehrwein Sven | Director | Open-market sale | −25,000 | $37.84 | 40,518 | Form 4 |
| 28 July 2026 | Doraiswamy Vinayak | Chief Scientific Officer | Open-market sale | −6,000 | $38.88 | 86,511 | Form 4 |
| 30 June 2026 | Carrel Michael H | President, CEO, & Director | Grant or award | +636 | $23.78 | 779,134 | Form 4 |
| 30 June 2026 | Privitera Salvatore | Chief Technical Officer | Grant or award | +636 | $23.78 | 158,684 | Form 4 |
| 30 June 2026 | Seith Douglas J | Chief Operating Officer | Grant or award | +527 | $23.78 | 229,867 | Form 4 |
| 30 June 2026 | Dahlquist Karl S. | Chief Legal Officer | Grant or award | +636 | $23.78 | 96,689 | Form 4 |
| 30 June 2026 | Doraiswamy Vinayak | Chief Scientific Officer | Grant or award | +636 | $23.78 | 92,511 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the AtriCure page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.